Cloderm Cream Recalled for Manufacturer Quality Assurance Program Discontinuation
EPI Health is recalling Cloderm cream due to discontinuation of the manufacturer's quality assurance program. This may result in products that do not meet specifications for identity, strength, purity, or quality.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall. The hazard is a manufacturing quality control deviation where the manufacturer's quality assurance program was discontinued. This creates theoretical risk that products may not meet specifications for identity, strength, purity, or quality. No illnesses or injuries are mentioned in the recall notice. Per the rubric, this is a risk-of-harm product where injury has not yet been reported, scoring as High.
Plain-English summary
Cloderm (clocortolone pivalate) Cream 0.1%, a topical corticosteroid medication, manufactured by EPI Health, LLC in Charleston, South Carolina, is being recalled. The product is available by prescription only in 45-gram tubes.
The recall was initiated due to a deviation from Current Good Manufacturing Practice (CGMP). The manufacturer discontinued its quality assurance program, which was designed to ensure that products meet specifications for identity, strength, purity, and quality. Without this program, products in circulation may not possess the characteristics they are represented to have.
The affected lot numbers are SDFC- (expiration date 5/31/2024) and TFBW- (expiration date 5/31/2025). Approximately 18,645 tubes were distributed nationwide. Patients who have this medication should consult their healthcare provider about continued use.
The recalled product
- Product
- Cloderm (clocortolone pivalate) Cream, 0.1%, Rx Only, For Topical Use Only, Net Wt 45g, Manufactured for: EPI Health, LLC, Charleston, SC 29403, NDC 71403-804-90
- Manufacturer
- EPI Health, LLC
- Category
- Drug — Topical / Corticosteroid
- Affected units
- 18,645
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- lot SDFC- exp. 5/31/2024 lot TFBW- exp. 5/31/2025
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by EPI Health, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · EPI Health, LLC
See all →- HighMinolira extended-release tablets recalled due to discontinued quality assurance program
FDA (Drugs) · 2024-05-01
- HighMinocycline Extended-Release Tablets Recalled for Manufacturing Quality Control Failure
FDA (Drugs) · 2024-05-01
- LowEPI Health Recalls Minolira Tablets for Dissolution Failures
FDA (Drugs) · 2019-10-02
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09